Zydus receives US FDA approval for anti-diabetic drug Nateglinide tablets USP
Zydus Cadila has received the final approval from the US FDA to market Nateglinide tablets USP in strengths of 60 mg and 120 mg.
The drug is an oral anti-diabetic agent used in the management of type 2 diabetes mellitus and will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad.
The group now has more than 100 approvals and has so far filed nearly 270 ANDAs since the commencement of the filing process in FY 2003-04.